Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MALACHITE INNOVATIONS, INC.

(MLCT)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vitality Biopharma, Inc. announced that it expects to receive $5 million in funding

08/19/2021 EST

Vitality Biopharma, Inc. announced that it has entered into a securities purchase agreement with a institutional investor for private placement of common shares for gross proceeds of up to $5,000,000 on August 19, 2021. The company will issue shares in tranches of up to $250,000 until the financing arrangement expires on December 31, 2022. The share price is equal to 85% of the lowest daily volume weighted average price during the 5 trading days prior the 3rd business day following its submission of the purchase notice. The company will also issue warrants at a price equal to 115% of the lowest daily volume weighted average price expires on the five-year anniversary of the date of issuance.


ę S&P Capital IQ 2021
All news about MALACHITE INNOVATIONS, INC.
11/15MALACHITE INNOVATIONS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
11/15Malachite Innovations, Inc. Reports Earnings Results for the Second Quarter and Six Mon..
CI
10/12VITALITY BIOPHARMA : ADOPTS NEW NAME – MALACHITE INNOVATIONS, INC - Form 8-K
PU
10/12VITALITY BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Amendments to Artic..
AQ
10/12VITALITY BIOPHARMA : Adopts New Name – Malachite Innovations, Inc.
GL
10/12Malachite Innovations, Inc. Announces Fiscal Year Change
CI
10/12Malachite Innovations, Inc. Announces Change of Corporate Headquarters
CI
10/12Malachite Innovations, Inc. has Changed its Ticker to MLCT from VBIO
CI
09/02Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility
GL
09/02VITALITY BIOPHARMA : ANNOUNCES EFFECTIVE S-1 REGISTRATION STATEMENT AND DTC ELIGIBILITY (F..
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -0,88 M - -
Net cash 2021 0,85 M - -
P/E ratio 2021 -10,4x
Yield 2021 -
Capitalization 17,8 M 17,8 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 3
Free-Float 66,9%
Chart MALACHITE INNOVATIONS, INC.
Duration : Period :
Malachite Innovations, Inc. Technical Analysis Chart | MLCT | US56089M1071 | MarketScreener
Income Statement Evolution
Managers and Directors
Michael Cavanaugh Chief Executive Officer & Director
Richard McKilligan Controller, Chief Financial & Accounting Officer
Edward F. Feighan Executive Chairman
Brandon Zipp Chief Science Officer
Richard F. Celeste Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MALACHITE INNOVATIONS, INC.420.83%16
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982